组蛋白去乙酰化酶1和2在前列腺癌中的表达及临床意义

Expressions of HDAC1 and HDAC2 in prostate cancer and their clinical implications

目的:检测组蛋白去乙酰化酶1(HDAC1)和组蛋白去乙酰化酶2(HDAC2)在前列腺癌中的表达情况,并探讨其临床意义。方法:选取82例临床资料完整的前列腺癌组织石蜡标本,免疫组化染色检测HDAC1和HDAC2蛋白的表达情况,分析其与Gleason分级、术前PSA水平、术后生存时间等指标的相关性。结果:免疫组化染色显示,前列腺癌组织中HDAC1和HDAC2的表达率分别为59.7%(49/82)、70.7%(58/82),定位于细胞核;Gleason评分高的患病组中HDAC1和HDAC2的表达高于Gleason评分低组,且在不同Gleason分级中表达差异有显著性(P均<0.05);HDAC1和HDAC2的表达在不同术前PSA水平、不同年龄分组中差异无统计学意义(P>0.05);单因素分析显示HDAC2、术前PSA水平、临床分期及Glesaon分级是影响前列腺癌患者生存的重要因素(P均<0.05);多因素回归分析表明HDAC2在前列腺癌中具有独立的预后意义(P=0.017,HR=2.265,95%CI:1.145～4.775)。结论:HDAC2在前列腺癌组织中表达升高并且具有独立的预后意义,为HDACs抑制剂在前列腺癌诊断中的应用和患者预后的判断提供了理论依据。

Objective： To detect the expressions of HDAC1 and HDAC2 proteins in prostate cancer and to explore their clinical significance. Methods ： We detected the expressions of HDAC1 and HDAC2 proteins in the tissue samples of prostate cancer from 82 patients with complete clinical data by immunohistochemistry, and analyzed the correlation of the expressions of HDAC1 and HDAC2 with other clinicopathological parameters, such as Gleason scores, preoperative PSA levels, and postoperative survival time. Results ： HDAC1 and HDAC2 were expressed in 59.7 and 70.7% of the patients, respectively, located in the nuclei of cancer cells, more highly in those with higher than in those with lower Gleason scores （ P 〈 0.05 ）. No statistically significant differences were found in the expressions of HDAC1 and HDAC2 among those with different preoperative PSA levels and those of different ages （ P 〉 0.05 ）. Univariate analysis demonstrated that the HDAC2 expression, pre-operative PSA levels, Gleason scores and clinical stages of prostate cancer were important factors affecting the patients survival （ P 〈 0.05 ）. Cox analysis indicated that the expression of HDAC2 was an independent index for the prognosis of prostate cancer （ P = 0. 017, HR = 2. 265,95% CI ： 1. 145 - 4. 775 ）. Conclusion ： The increased expression of HDAC2 in prostate cancer can serve as an independent prognostic indicator, which has provided a theoretical base for the clinical application of HDACs in the diagnosis and prognosis of prostate cancer.